Inhaled corticosteroid/long-acting β2-agonist combination therapy for asthma: Attitudes of specialists in Europe

International Archives of Allergy and Immunology

Volumn 157, Issue 3, 2012, Pages 303-310

  Bousquet, Jean ^a   Winchester, Chris ^c,d   Papi, Alberto ^f   Virchow, J Christian ^g   Haughney, John ^c   Costa, David ^b   Usmani, Omar ^e   Bjermer, Leif ^h   Price, David ^c  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d OXFORD PHARMAGENESIS LTD   (United Kingdom)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f UNIVERSITY OF FERRARA   (Italy)

^g University Medical Centre Rostock   (Germany)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Asthma; Delphi process; Inhaled corticosteroid; Long acting 2 agonist

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; IMMUNOMODULATING AGENT; STEROID; XANTHINE DERIVATIVE;

ARTICLE; ASTHMA; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; HUMAN; MEDICAL SPECIALIST; PERCEPTION; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; ADULT; ALLERGY AND IMMUNOLOGY; ANTI-ASTHMATIC AGENTS; ASTHMA; ATTITUDE OF HEALTH PERSONNEL; DELPHI TECHNIQUE; DRUG COMBINATIONS; EUROPE; FEMALE; HUMANS; MALE; PHYSICIANS; PULMONARY MEDICINE;

EID: 80155182205     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000329519     Document Type: Article

References (28)

1. GINA report: Global strategy for asthma management and prevention. Global Initiative for Asthma, 2009. http://www.ginasthma. org (accessed March 25, 2010).
2. Price D, Ali M, Burden A, Chisholm A, Lee AJ, Kemp L, et al: Effectiveness of combination therapies: Real-world versus randomized controlled trials (abstract 48). Prim Care Respir J 2010; 19:A13.
3. Rabe KF, Vermeire PA, Soriano JB, Maier WC: Clinical management of asthma in 1999: The Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802-807. (Pubitemid 32049363)
4. Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I, et al: Asthma control in Europe: A real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007; 120: 1360-1367. (Pubitemid 350225685)
5. Peters SP, Jones CA, Haselkorn T, Mink DR, Valacer DJ, Weiss ST: Real-world Evaluation of Asthma Control and Treatment (REACT): Findings from a national Web-based survey. J Allergy Clin Immunol 2007; 119: 1454-1461. (Pubitemid 46863372)
6. Haughney J, Price D, Kaplan A, Chrystyn H, Horne R, May N, et al: Achieving asthma control in practice: Understanding the reasons for poor control. Respir Med 2008; 102: 1681-1693.
7. Horne R, Price D, Cleland J, Costa R, Covey D, Gruffydd-Jones K, et al: Can asthma control be improved by understanding the patient's perspective? BMC Pulm Med 2007; 7: 8.
8. Price D: Trends in prescribing of inhaled corticosteroids alone and in combination with long-acting beta2-agonists in Europe in 2004-2009. World Allergy Congress, Dubai, 5-8 December 2010, submitted.
9. Zhang T, Carleton BC, Prosser RJ, Smith AM: The added burden of comorbidity in patients with asthma. J Asthma 2009; 46: 1021-1026.
10. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al: Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 143-178.
11. Abdullah AK, Khan S: Evidence-based selection of inhaled corticosteroid for treatment of chronic asthma. J Asthma 2007; 44: 1-12.
12. Hübner M, Hochhaus G, Derendorf H: Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am 2005; 25: 469-488. (Pubitemid 41073457)
13. Lotvall J, Ankerst J: Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients. Respir Med 2008; 102: 449-456. (Pubitemid 351193035)
14. Murphy VE, Fittock RJ, Zarzycki PK, Delahunty MM, Smith R, Clifton VL: Metabolism of synthetic steroids by the human placenta. Placenta 2007; 28: 39-46. (Pubitemid 44734614)
15. Palmqvist M, Ibsen T, Mellen A, Lotvall J: Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 244-249. (Pubitemid 29326095)
16. Adams N, Bestall JM, Jones PW: Inhaled beclomethasone versus budesonide for chronic asthma. Cochrane Database Syst Rev 2002:CD003530.
17. Dalkey N: An experimental study of group opinion: The Delphi method. Futures 1969; 1: 408-426.
18. Thompson M: Considering the implication of variations within Delphi research. Fam Pract 2009; 26: 420-424.
19. Fernandez-Benitez M, Ibero Iborra M, Sanz Ortega J, Garde J: Delphi project in bronchial asthma. Two stages. Allergol Immunopathol (Madr) 2010; 38: 295-299.
20. Harding G, Leidy NK, Meddis D, Kleinman L, Wagner S, O'Brien CD: Interpreting clinical trial results of patient-perceived onset of effect in asthma: Methods and results of a Delphi panel. Curr Med Res Opin 2009; 25: 1563-1571.
21. Andreas S, Hering T, Muhlig S, Nowak D, Raupach T, Worth H: Smoking cessation in chronic obstructive pulmonary disease: An effective medical intervention. Dtsch Arztebl Int 2009; 106: 276-282.
22. Sheikh A, Major P, Holgate ST: Developing consensus on national respiratory research priorities: Key findings from the UK Respiratory Research Collaborative's e-Delphi exercise. Respir Med 2008; 102: 1089-1092.
23. Jones MI, Greenfield SM, Bradley CP: Prescribing new drugs: Qualitative study of influences on consultants and general practitioners. BMJ 2001; 323: 378-381. (Pubitemid 32762465)
24. Grande D, Frosch DL, Perkins AW, Kahn BE: Effect of exposure to small pharmaceutical promotional items on treatment preferences. Arch Intern Med 2009; 169: 887-893.
25. Vancelik S, Beyhun NE, Acemoglu H, Calikoglu O: Impact of pharmaceutical promotion on prescribing decisions of general practitioners in Eastern Turkey. BMC Public Health 2007; 7: 122.
26. Chowdhury BA, Dal Pan G: The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010; 362: 1169-1171.
27. Beasley R, Perrin K, Weatherall M, Wijesinghe M: Call for withdrawal of LABA singletherapy inhaler in asthma. Lancet 2010; 376: 750-751.
28. Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, et al: Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007; 102: 1417-1426. (Pubitemid 46976288)